Myelodysplastic Syndrome (MDS) Market Spotlight, 2017-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Myelodysplastic Syndrome (MDS)” report has been
added to ResearchAndMarkets.com’s offering.

This Market Spotlight report covers the myelodysplastic syndrome market,
comprising key marketed and pipeline drugs, recent events and analyst
opinion, clinical trials, probability of success, upcoming events,
patent information, a 10-year disease incidence forecast, and licensing
and acquisition deals, as well as presenting drug-specific revenue
forecasts

Key Takeaways

• The estimates that in 2017, there were 367,200 incident cases of
  myelodysplastic syndrome (MDS) worldwide, and forecasts that number to
  increase to 401,700 incident cases by 2026.
• Approved drugs in the MDS space target DNA methyltransferase, BCR-ABL
  fusion protein, KIT/c-KIT, platelet-derived growth factor receptor,
  erythropoietin receptor, angiogenesis, E3 ubiquitin ligase, and the
  immune system. These therapies are administered via the intravenous,
  oral, and subcutaneous routes.
• The greatest proportion of industry-sponsored drugs in active clinical
  development for MDS are in Phase II. Therapies in development for MDS
  focus on a wide variety of targets. The majority of pipeline drugs in
  the MDS space are administered via the intravenous or oral routes,
  with the remainder being subcutaneous or intradermal formulations.
• High-impact upcoming events for drugs in the MDS space comprise
  topline Phase II and Phase III trial results. The overall likelihood
  of approval of a Phase I hematologic asset is 10.7%, and the average
  probability a drug advances from Phase III is 57.6%. Drugs, on
  average, take 8.7 years from Phase I to approval, compared to 9.2
  years in the overall oncology space.
• There have been 18 licensing and asset acquisition deals involving MDS
  drugs during 2014-19. The $1.8bn exclusive global collaboration and
  license agreement made in December 2018 between Argenx and Cilag to
  evaluate cusatuzumab (ARGX-110), an anti-CD70 SIMPLE Antibody, in
  acute myeloid leukemia (AML), high-risk MDS, and other hematological
  malignancies was the largest deal during the period.
• The distribution of clinical trials across Phase I-IV indicates that
  the vast majority of trials for MDS have been in the early and
  mid-phases of development, with 89% of trials in Phase I-II, and only
  11% in Phase III-IV.
• The US has a substantial lead in the number of MDS clinical trials
  globally. France leads the major EU markets, while Japan has the top
  spot in Asia.
• Clinical trial activity in the MDS space is dominated by completed
  trials. Celgene has the highest number of completed clinical trials
  for MDS, with 91 trials.
• Celgene leads the industry sponsors with by far the highest number of
  clinical trials for MDS.

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

MDS subtypes

TREATMENT

Supportive therapy

Growth factors

Chemotherapy

Immune treatments

Stem cell transplant

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Luspatercept for MDS (December 2, 2018)

Luspatercept for MDS (June 28, 2018)

Imetelstat for MDS (July 31, 2017)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

Impressive Clinical Results For Argenx’s Oncology Candidate Seal The
Deal for Janssen

Onconova Grants Latin American Rigosertib Rights To Pint Pharma

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

Recent events

BIBLIOGRAPHY

Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/7jo1ve

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Leukemia
Drugs